Japanese drugmaker Takeda has suspended dosing in phase 2 trials of its orexin agonist TAK-994, saying it had encountered a "safety signal" in the study. The future of the programme seems to be in ...

Centessa Pharmaceuticals, founded from the merger of 10 biotech companies, is based on an asset-centric model, primarily developing its lead orexin agonist, ORX-750. ORX-750 targets narcolepsy ...

At the start of each of the last five years, the share price of Alkermes has increased. It’s the kind of steady trajectory ...

Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda ...

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

The company’s strong focus on its orexin receptor-2 (OX2R) franchise, which is seen as a leader in addressing sleep-wake disorders, is a significant reason for this positive outlook. The ...

Spiromacrocyclic compounds acting as orexin OX2 receptor agonists have been described in an H. Lundbeck A/S patent and reported to be useful for the treatment of type 1 and type 2 narcolepsy.

Recently, we announced details around our preclinical program to evaluate two candidates, AEX-41 and AEX-2, two first-in-class non-sulfonamide DOXAs designed to target both orexin-1 and orexin-2 ...